

Journalbeiträge

1. Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, Küppers R, Lenze D, Ott G, Pott C, Richter J, Rosenwald A, Szczepanowski M, Schwaenen C, Stein H, Trautmann H, Wessendorf S, Trümper L, Loeffler M, Spang R, Kluin PM, Klapper W, Siebert R, Molecular Mechanisms in Malignant Lymphomas Network Project (2014) Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. HAEMATOLOGICA 99(4): 726-35, doi: 10.3324/haematol.2013.091827
2. Avivi I, Canals C, Vernant JP, Wulf G, Nagler A, Hermine O, Petersen E, Yakoub-Agha I, Craddock C, Schattenberg A, Niederwieser D, Thomson K, Blaise D, Attal M, Pfreundschuh M, Passweg J, Russell N, Dreger P, Sureda A, EBMT Lymphoma Working Party (2014) Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma. BONE MARROW TRANSPL 49(5): 671-8, doi: 10.1038/bmt.2014.4
3. Binder C, Chuang E, Habla C, Bleckmann A, Schulz M, Bathgate R, Einspanier A (2014) Relaxins enhance growth of spontaneous murine breast cancers as well as metastatic colonization of the brain. CLIN EXP METASTAS 31(1): 57-65, doi: 10.1007/s10585-013-9609-2
4. Braulke F, Füzesi L, Trümper L, Bäsecke J (2014) Littoral Cell Angiomatosis: Splenic Lesions in a Patient with Follicular Non Hodgkin Lymphoma. J Cytol Histol 5: 232
5. Budde H, Kolb S, Salinas Tejedor L, Wulf G, Reichardt HM, Riggert J, Legler TJ (2014) Modified extracorporeal photopheresis with cells from a healthy donor for acute graft-versus-host disease in a mouse model. PLOS ONE 9(8): e105896, doi: 10.1371/journal.pone.0105896
6. Coiffier B, Federico M, Caballero D, Dearden C, Morschhauser F, Jäger U, Trümper L, Zucca E, Gomes da Silva M, Pettengell R, Weidmann E, d'Amore F, Tilly H, Zinzani PL (2014) Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. CANCER TREAT REV 40(9): 1080-8, doi: 10.1016/j.ctrv.2014.08.001
7. Fenaux P, Haase D, Sanz GF, Santini V, Buske C, ESMO Guidelines Working Group (2014) Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANN ONCOL 25 Suppl 3: iii57-69, doi: 10.1093/annonc/mdu180
8. Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M, Silling G, Wilhelm C, Zeis M, Görlitz A, Pfeiffer S, Hilgers R, Truemper L, Schmitz N, German High-Grade Lymphoma Study Group (2014) Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. LANCET ONCOL 15(7): 757-66, doi: 10.1016/S1470-2045(14)70161-5
9. Hasenkamp J, Bleckmann A, Mekolli A (2014) [71-year-old patient with loss of appetite, urge to defecate, and diarrhea]. DEUT MED WOCHENSCHR 139(18): 941-2, doi: 10.1055/s-0034-1369933
10. Hohloch K, Zeynalova S, Held G, Ziepert M, Loeffler M, Wulf G, Schmitz N, Pfreundschuh M, Trümper L (2014) Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens. LEUKEMIA 28(11): 2260-3, doi: 10.1038/leu.2014.213
11. Hohloch K, Bertram N, Trümper L, Beissbarth T, Griesinger F (2014) Superior vena cava syndrome caused by a malignant tumor: a retrospective single-center analysis of 124 cases. J CANCER RES CLIN 140(12): 2129-34, doi: 10.1007/s00432-014-1764-6
12. Hohloch K, Lankeit HK, Zinzani PL, Scholz CW, Lorschbach M, Windemuth-Kieselbach C, Trümper L (2014) Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network. EUR J NUCL MED MOL I 41(8): 1585-92, doi: 10.1007/s00259-014-2758-y
13. Hohloch K, Zwick C, Ziepert M, Hasenclever D, Kaiser U, Engert A, Höffkes HG, Kroschinsky F, Mesters R, Feller AC, Löffler M, Trümper L, Pfreundschuh M, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) (2014) Significant dose Escalation of Idarubicin in the treatment of aggressive Non-Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL. Springerplus 3: 5, doi: 10.1186/2193-1801-3-5
14. Homayounfar K, Bleckmann A, Helms HJ, Lordick F, Rüschoff J, Conradi LC, Sprenger T, Ghadimi M, Liersch T (2014) Discrepancies between medical oncologists and surgeons in assessment of resectability and indication for chemotherapy in patients with colorectal liver metastases. BRIT J SURG 101(5): 550-7, doi: 10.1002/bjs.9436
15. Klingenberg M, Becker J, Eberth S, Kube D, Wilting J (2014) The chick chorioallantoic membrane as an in vivo xenograft model for Burkitt lymphoma. BMC CANCER 14: 339, doi: 10.1186/1471-2407-14-339
16. Klingenberg M, Becker J, Eberth S, Kube D, Wilting J (2014) The NADPH oxidase inhibitor imipramine-blue in the treatment of Burkitt lymphoma. MOL CANCER THER 13(4): 833-41, doi: 10.1158/1535-7163.MCT-13-0688

17. Koch R, Demant M, Aung T, Diering N, Cicholas A, Chapuy B, Wenzel D, Lahmann M, Güntsch A, Kiecke C, Becker S, Hupfeld T, Venkataramani V, Ziepert M, Opitz L, Klapper W, Trümper L, Wulf GG (2014) Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma. *BLOOD* 123(14): 2189-98, doi: 10.1182/blood-2013-08-523886
18. König S, Nitzki F, Uhmann A, Dittmann K, Theiss-Suennemann J, Herrmann M, Reichardt HM, Schwendener R, Pukrop T, Schulz-Schaeffer W, Hahn H (2014) Depletion of cutaneous macrophages and dendritic cells promotes growth of basal cell carcinoma in mice. *PLOS ONE* 9(4): e93555, doi: 10.1371/journal.pone.0093555
19. Markus MA, Dullin C, Mitkovski M, Prieschl-Grassauer E, Epstein MM, Alves F (2014) Non-invasive optical imaging of eosinophilia during the course of an experimental allergic airways disease model and in response to therapy. *PLOS ONE* 9(2): e90017, doi: 10.1371/journal.pone.0090017
20. Mei M, Wondergem MJ, Palmer JM, Shimoni A, Hasenkamp J, Tsai NC, Simpson J, Nademanee A, Raubitschek A, Forman SJ, Krishnan AY (2014) Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen. *BIOL BLOOD MARROW TR* 20(12): 2072-5, doi: 10.1016/j.bbmt.2014.07.028
21. Menck K, Behme D, Pantke M, Reiling N, Binder C, Pukrop T, Klemm F (2014) Isolation of human monocytes by double gradient centrifugation and their differentiation to macrophages in teflon-coated cell culture bags. *J Vis Exp N.N.*(91): e51554, doi: 10.3791/51554
22. Menke J, Pauli S, Sigler M, Kühnle I, Shoukier M, Zoll B, Ganster C, Salinas-Riester G, Schaefer IM (2014) Uniparental Trisomy of a Mutated HRAS Proto-Oncogene in Embryonal Rhabdomyosarcoma of a Patient With Costello Syndrome. *J CLIN ONCOL* 33(13): e62-e65, doi: 10.1200/JCO.2013.49.6539
23. Mohammadi S, Larsson E, Alves F, Dal Monego S, Biffi S, Garrovo C, Lorenzon A, Tromba G, Dullin C (2014) Quantitative evaluation of a single-distance phase-retrieval method applied on in-line phase-contrast images of a mouse lung. *J SYNCHROTRON RADIAT* 21(Pt 4): 784-9, doi: 10.1107/S1600577514009333
24. Müller-Thomas C, Rudelius M, Rondak IC, Haferlach T, Schanz J, Huberle C, Schmidt B, Blaser R, Kremer M, Peschel C, Germing U, Platzbecker U, Götze K (2014) Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia. *HAEMATOLOGICA* 99(10): e179-81, doi: 10.3324/haematol.2014.104760
25. Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hänel M, Held G, Schmitz N, Viardot A, Schmidt C, Hallek M, Witzens-Harig M, Trümper L, Rixecker T, Zwick C (2014) Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. *ANN ONCOL* 25(9): 1800-6, doi: 10.1093/annonc/mdu208
26. Pfreundschuh M, Poeschel V, Zeynalova S, Hänel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MHJ, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N (2014) Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. *J CLIN ONCOL* 32(36): 4127-33, doi: 10.1200/JCO.2013.54.6861
27. Platzbecker U, Al-Ali HK, Gattermann N, Haase D, Janzen V, Krauter J, Götze K, Schlenk R, Nolte F, Letsch A, Ottmann OG, Kündgen A, Lübbert M, Germing U, Wermke M, Reinhard H, Weiss C, Lieder K, Ehninger G, Leismann O, Giagounidis A (2014) Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients. *LEUKEMIA* 28(3): 696-8, doi: 10.1038/leu.2013.325
28. Puls M, Bleckmann A, Jacobshagen C, Danner BC, Hasenfuß G, Seipelt R, Schillinger W (2014) [Diabetes increases short- and long-term mortality after transcatheter aortic valve implantation (TAVI)]. *DEUT MED WOCHENSCHR* 139(16): 822-8, doi: 10.1055/s-0034-1369863
29. Puls M, Sobisiak B, Bleckmann A, Jacobshagen C, Danner BC, Hünlich M, Beißbarth T, Schöndube F, Hasenfuß G, Seipelt R, Schillinger W (2014) Impact of frailty on short- and long-term morbidity and mortality after transcatheter aortic valve implantation: risk assessment by Katz Index of activities of daily living. *EUROINTERVENTION* 10(5): 609-19, doi: 10.4244/EIJY14M08_03
30. Salaverria I, Martin-Guerrero I, Wagener R, Kreuz M, Kohler CW, Richter J, Pienkowska-Grela B, Adam P, Burkhardt B, Claviez A, Damm-Welk C, Drexler HG, Hummel M, Jaffe ES, Küppers R, Lefebvre C, Lisfeld J, Löffler M, Macleod RAF, Nagel I, Oschlies I, Rosolowski M, Russell RB, Rymkiewicz G, Schindler D, Schlesner M, Scholtysik R, Schwaenen C, Spang R, Szczepanowski M, Trümper L, Vater I, Wessendorf S, Klapper W, Siebert R, Molecular Mechanisms in Malignant Lymphoma Network Project, Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group (2014) A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. *BLOOD* 123(8): 1187-98, doi: 10.1182/blood-2013-06-507996
31. Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, Held G, Brossart P, Lübbert M, Salih HR, Kindler T, Horst HA, Wulf G, Nachbaur D, Götze K, Lamparter A, Paschka P, Gaidzik VI, Teleanu V, Späth D, Benner A, Krauter J, Ganser A, Döhner H, Döhner K, German-Austrian AML Study Group (2014)

- Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. BLOOD 124(23): 3441-9, doi: 10.1182/blood-2014-05-578070
32. Schuelper N, Flohr A, Trümper L, Wulf GG (2014) Osteolytic lesions in patients with relapse of diffuse large B-cell lymphoma treated with lenalidomide. ANN HEMATOL 93(11): 1929-30, doi: 10.1007/s00277-014-2071-7
 33. Sebastian M, Niederle N, Thomas M, Reck M, Schmittel A, Fischer B, Overbeck T, Gröschel A, Deppermann M, Pirker R, Huber RM, Eberhardt W, Griesinger F (2014) [Molecular genetic tests in advanced non-small cell lung cancer: practical relevance]. DEUT MED WOCHENSCHR 139(41): 2096-100, doi: 10.1055/s-0034-1387294
 34. Straube C, Derry S, Jackson KC, Wiffen PJ, Bell RF, Strassels S, Straube S (2014) Codeine, alone and with paracetamol (acetaminophen), for cancer pain. COCHRANE DB SYST REV 9: CD006601, doi: 10.1002/14651858.CD006601.pub4
 35. Stübiger T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T, Wolschke C, Ayuk F, Kröger N (2014) JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. LEUKEMIA 28(8): 1736-8, doi: 10.1038/leu.2014.86
 36. Szusies CJ, Hasenkamp J, Jung W, Koch R, Trümper L, Wulf GG (2014) Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy. INT J HEMATOL 100(5): 425-8, doi: 10.1007/s12185-014-1678-8
 37. Tassara M, Döhner K, Brossart P, Held G, Götze K, Horst HA, Ringhoffer M, Köhne CH, Kremers S, Raghavachar A, Wulf G, Kirchen H, Nachbaur D, Derigs HG, Wattad M, Koller E, Brugger W, Matzdorff A, Greil R, Heil G, Paschka P, Gaidzik VI, Göttlicher M, Döhner H, Schlenk RF (2014) Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. BLOOD 123(26): 4027-36, doi: 10.1182/blood-2013-12-546283
 38. Unsöld B, Kaul A, Sbroggiò M, Schubert C, Regitz-Zagrosek V, Brancaccio M, Damilano F, Hirsch E, Van Bilsen M, Munts C, Sipido K, Bito V, Detre E, Wagner NM, Schäfer K, Seidler T, Vogt J, Neef S, Bleckmann A, Maier LS, Balligand JL, Bouzin C, Ventura-Clapier R, Garnier A, Eschenhagen T, El-Armouche A, Knöll R, Tarone G, Hasenfuß G (2014) Melusin protects from cardiac rupture and improves functional remodelling after myocardial infarction. CARDIOVASC RES 101(1): 97-107, doi: 10.1093/cvr/cvt235
 39. Wulf GG, Trümper L (2014) [Treatment of peripheral T-cell lymphoma]. DEUT MED WOCHENSCHR 139(23): 1213-5, doi: 10.1055/s-0034-1370064
 40. Zatula N, Wiese M, Bunzendahl J, Birchmeier W, Perske C, Bleckmann A, Brembeck FH (2014) The BCL9-2 proto-oncogene governs estrogen receptor alpha expression in breast tumorigenesis. ONCOTARGET 5(16): 6770-87

Buchbeiträge

1. Hohloch K, Chapuy B, Trümper L (2014) Yttrium-90 Ibritumomab Tiuxetan (Zevalin). In: Stefan Dübel und Janice M. Reichert (Hrsg.) Handbook of Therapeutic Antibodies, Volume 3: Approved Therapeutic Antibodies. Wiley-Blackwell, Oxford, 1579 - 1598
2. Markus M, Dullin C, Alves F (2014) 4.15 - Two-Dimensional In Vivo Fluorescence Imaging. In: A. Brahme (Hrsg.) Comprehensive Biomedical Physics. Elsevier, 227 - 243
3. Napp J, Alves F (2014) Bio-optical Imaging. In: A. Brahme (Hrsg.) Comprehensive Biomedical Physics. Elsevier, 1 -14
4. Schanz J, Haase D (2014) Cytogenetic features of Myelodysplastic Syndromes. In: Germing U, Haas R (Hrsg.) Novel Insights into Pathophysiology, Diagnostics and Treatment of Myelodysplastic Syndromes. Future Medicine Ltd, London, 49-69
5. Trümper L, Uppenkamp M, Schmidberger H, Dornoff W (2014) B- und T-Zell-Lymphome (NHL). In: Preis, Dornoff, Schmieder, Honecker, Claßen (Hrsg.) Taschenbuch Onkologie 2014/15, Interdisziplinäre Empfehlungen zur Therapie. W. Zuckschwerdt Verlag GmbH, 15 - 30

Habilitationen

1. Schanz J (2014) Individualisierte prognostische Klassifikation zytogenetischer Aberrationen bei Patienten mit Myelodysplastischen Syndromen (MDS). Habilitation Universität Göttingen.

Medizinische Dissertationen

1. Gerlach B, Dr. med. (2014) Retrospektive Analyse der Bedeutung mikroangiopathischer Veränderungen bei Patienten unter extrakorporaler Photopherese als Therapie einer GvHD. Dissertation Universität Göttingen.
2. Götz NS, Dr. med. (2014) Zur Durchführbarkeit von spezifischer zytostatischer Therapie bei Patienten mit malignen Erkrankungen in höherem Lebensalter - Retrospektive unizentrische Analyse zur Toxizität und Effektivität einer Hochdosischemotherapie (BEAM) mit autologer Stammzelltransplantation bei Patienten mit rezidiviertem Lymphom im Alter über 60 Jahre. Dissertation Universität Göttingen.
3. Troendlin F, Dr. med. (2014) Einsatz von Vibrationstraining als supportive Maßnahme begleitend zu allogenen hämatopoetischen Stammzelltransplantationen - Pilotstudie zu Sicherheit, Machbarkeit und Effektivität. Dissertation Universität Göttingen.

4. Wermuth JM, Dr. med. (2014) Die Rolle von Zytokin- und Zytokinrezeptorgenvariationen für die Ausprägung von GvHD und GvL nach allogener Blutstammzelltransplantation bei Patienten mit hämatologischer Neoplasie. Dissertation Universität Göttingen.

5.

Naturwiss. u.a. nichtmed. Diss.

1. Menck K, Dr. rer. nat. (2014) Extracellular vesicles as mediators of intercellular communication in human breast cancer progression. Dissertation Georg-August-Universität Göttingen.